Use Intermountain Connect Care®
Get care for low-level urgent conditions through a video chat with a provider, 24/7, on your computer or mobile device.
Learn More.
Learn More.
The formation of the Cancer MoonShot 2020 Pediatrics Consortium was announced on Feb. 18, 2016 in Phoenix, Ariz. The Consortium brings together national representatives of academic institutions and leading children’s hospitals to significantly advance immunotherapy cancer treatments by 2020. Dr. Schiffman’s work includes the discovery of cancer-fighting genes in elephants that may hold answers for cancer treatment in humans.
Dr. Schiffman, who is one of the Consortium’s 10 founding members, works at Intermountain Primary Children’s Hospital and is a Professor of Pediatrics at the University of Utah and an Investigator at the Huntsman Cancer Institute. He said he is pleased that Utah and its children can contribute to the pediatric cancer initiative. “This effort offers a unique and timely opportunity to harness the power of genomic translation to eventually help the nearly 16,000 children diagnosed with cancer each year in the United States.”
The Cancer MoonShot 2020 Pediatrics Consortium is characterized as a major milestone in the war on pediatric cancer. It includes collaborative efforts to reduce barriers to faster progress in pediatric cancer treatments, with the ultimate goal of significantly advancing immunotherapy cancer treatments by 2020.
Cancer MoonShot 2020 is a historic, national coalition formed to accelerate next-generation immunotherapy to subdue cancer by the turn of the next decade.
Read and download the full press release.
Dr. Joshua Schiffman, a pediatric oncologist at Intermountain Primary Children’s Hospital known for his cancer research with elephants, is part of a national Cancer MoonShot 2020 team aimed at speeding the progress of pediatric cancer treatments.